Severity: Warning
Message: fopen(/var/lib/php/sessions/ci_session095iggn4sjrrfeihnislmoopmjv6sho2): Failed to open stream: No space left on device
Filename: drivers/Session_files_driver.php
Line Number: 177
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
Severity: Warning
Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)
Filename: Session/Session.php
Line Number: 137
Backtrace:
File: /var/www/html/index.php
Line: 316
Function: require_once
The designation of 'arrhythmogenic cardiomyopathy' reflects the evolving concept of a heart muscle disease affecting not only the right ventricle (ARVC) but also the left ventricle (LV), with phenotypic variants characterized by a biventricular (BIV) or predominant LV involvement (ALVC). Herein, we use the term 'scarring/arrhythmogenic cardiomyopathy (S/ACM)' to emphasize that the disease phenotype is distinctively characterized by loss of ventricular myocardium due to myocyte death with subsequent fibrous or fibro-fatty scar tissue replacement. The myocardial scarring predisposes to potentially lethal ventricular arrhythmias and underlies the impairment of systolic ventricular function. S/ACM is an 'umbrella term' which includes a variety of conditions, either genetic or acquired (mostly post-inflammatory), sharing the typical 'scarring' phenotypic features of the disease. Differential diagnoses include 'non-scarring' heart diseases leading to either RV dilatation from left-to-right shunt or LV dilatation/dysfunction from a dilated cardiomyopathy. The development of 2020 upgraded criteria ('Padua criteria') for diagnosis of S/ACM reflected the evolving clinical experience with the expanding spectrum of S/ACM phenotypes and the advances in cardiac magnetic resonance (CMR) imaging. The Padua criteria aimed to improve the diagnosis of S/ACM by incorporation of CMR myocardial tissue characterization findings. Risk stratification of S/ACM patients is mostly based on arrhythmic burden and ventricular dysfunction severity, although other ECG or imaging parameters may have a role. Medical therapy is crucial for treatment of ventricular arrhythmias and heart failure. Implantable cardioverter defibrillator (ICD) is the only proven life-saving treatment, despite its significant morbidity because of device-related complications and inappropriate shocks. Selection of patients who can benefit the most from ICD therapy is one of the most challenging issues in clinical practice.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10132624 | PMC |
http://dx.doi.org/10.1093/eurheartjsupp/suad017 | DOI Listing |
Int Heart J
March 2025
Department of Cardiology, Nagoya University Graduate School of Medicine.
The prognostic value of defibrillators in cardiac resynchronization therapy (CRT) for primary prevention remains debatable. Predicting ventricular arrhythmias (VAs) before implantation is useful for deciding whether to add a defibrillator to a CRT device. This study aimed to determine the risk factors for VA events after CRT device implantation and to construct a scoring model.
View Article and Find Full Text PDFCardiol Ther
March 2025
Division of Cardiology, Christus Good Shepherd Medical Center, Longview, TX, USA.
Introduction: Anthracyclines treat a myriad of malignancies; however, they are known to lead to cancer therapy-related cardiomyopathy (CTRC). Randomized controlled trials (RCTs) evaluating the role of angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) in primary prevention of CTRC have yielded mixed results.
Methods: A systematic search of MEDLINE, Cochrane, and Scopus databases was performed to identify RCTs that evaluated outcomes in patients receiving anthracyclines and ACEi or ARBs versus control.
Sci Rep
March 2025
Ludwig Boltzmann Institute for Cardiovascular Research at the Center for Biomedical Research and Translational Surgery, Medical University of Vienna, 1090, Vienna, Austria.
Duchenne muscular dystrophy (DMD), a severe muscle disease caused by mutations in the gene encoding for the intracellular protein dystrophin, is associated with impaired cardiac function and arrhythmias. A causative factor for complications in the dystrophic heart is abnormal calcium (Ca) handling in ventricular cardiomyocytes, and restoration of normal Ca homeostasis has emerged as therapeutic strategy. Here, we used a rodent model of DMD, the dystrophin-deficient DMD rat, to test the following hypothesis: chronic administration of ivabradine (IVA), a drug clinically approved for the treatment of heart failure, improves Ca handling in dystrophic ventricular cardiomyocytes and thereby enhances contractile performance in the dystrophic heart.
View Article and Find Full Text PDFHeart Rhythm
March 2025
Department of Cardiology, Amsterdam University Medical Center, Amsterdam, the Netherlands; School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom. Electronic address:
Background: Late gadolinium enhancement (LGE) images, reconstructed using magnitude (MAG) or phase-sensitive inversion recovery (PSIR), differ in signal intensities due to their handling of longitudinal magnetization. These differences influence LGE quantification, which typically uses Full Width at Half Maximum (FWHM) or standard deviation (n-SD) thresholding when predicting cardiac events.
Objective: This study assessed the impact of FWHM and n-SD on MAG- and PSIR-derived scar characteristics.
Heart Rhythm
March 2025
Amsterdam Academic Medical Center, Amsterdam, The Netherlands.
Background: Initial results were recently reported for the AVEIR DR i2i study which involved the percutaneous implantation of a novel dual-chamber leadless pacemaker (LP) system, with right atrial (RA) and ventricular (RV) LPs delivering atrioventricular synchronous pacing.
Objective: Evaluate procedural outcomes and learning curve for de novo implantation of the dual-chamber LP (AVEIR DR™, Abbott).
Methods: Implant procedure metrics collected during the study were analyzed, including procedural complications within 30 days post-implant.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!